- AstraZeneca’s pipeline struggles continue as it reports disappointing data in cancer, rare diseaseAstraZeneca said Monday that two key late-stage trials yielded subpar results — one testing an antibody-drug conjugate in stomach cancer and the other evaluating Ultomiris in a rare disease. The…Endpoints · 4m ago↗ source
- Schrödinger debuts AI agent Bunsen to use its physics softwareThree years ago, Schrödinger CEO Ramy Farid ruffled some feathers by pushing back on the AI fever of the moment. He said AI hype was at "dangerous" and "insane" levels, warning there ...Endpoints · 7m ago↗ source
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2BArgenx will spend $2.2 billion to buy Forte Biosciences and its anti-CD122 monoclonal antibody that’s under investigation for autoimmune diseases. The Belgian-Dutch pharma said Monday it will pay…